News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
Clinical - Pre-Clinical
Canopus BioPharma, Inc. Announces Positive Results From An In-Vitro Live Ebola Virus Study 12/19/2014
PTC Therapeutics, Inc. (PTCT) Release: Translarna Granted Orphan Drug Designation In The U.S. And Europe For The Treatment Of Mucopolysaccharidosis I 12/19/2014
Novogen Limited (NVGN) Announces Breakthrough Discovery In The Treatment Of Melanoma 12/16/2014
Nuvilex (NVLX) Provides Shareholder Update On Cancer And Diabetes Programs 12/16/2014
Vaccinex, Inc. Announces Publication Of Preclinical Studies With An Anti-SEMA4D Antibody In Animal Models Of Neuroinflammatory And Demyelinating Disease 12/12/2014
Syros Pharmaceuticals Announces New Research Published On CDK7 In Lung And Pediatric Cancers 12/11/2014
Enzyme Bio-Systems Ltd. Release: Preclinical Xenograft Studies Show Positive Results For Amooranin 12/11/2014
Kadmon Corporation Presents Preclinical Data On KD025 In Chronic Graft-Versus-Host-Disease At American Society of Hematology Annual Meeting 12/10/2014
Celator Pharmaceuticals, Inc. Presents Data On CPX-351 At The 56th American Society of Hematology Annual Meeting 12/10/2014
NIH Publishes Results Of Preclinical Collaboration With ChromaDex, Inc. Showing Potential Benefit Of Nicotinamide Riboside 12/10/2014
Epizyme (EPZM) First-In-Class PRMT5 Inhibitor Demonstrates In Vitro And In Vivo Activity In Models Of Mantle Cell Lymphoma 12/9/2014
GlycoMimetics, Inc. (GLYC) Highlights Potential Therapeutic Benefits Of Its Novel E-Selectin Antagonist At 56th American Society of Hematology Annual Meeting 12/9/2014
Fate Therapeutics (FATE) Highlights Effects Of Nutrient-Rich Media On Ex Vivo Programmed CD34+ Cells Sourced From Umbilical Cord Blood 12/9/2014
Aptose Biosciences Presents APTO-253 Preclinical Data At 56th American Society of Hematology Annual Meeting 12/9/2014
Geron Corporation (GERN) Announces Publication Of Preclinical Data On Imetelstat Activity In Acute Myelogenous Leukemia 12/8/2014
Blueprint Medicines Debuts Comprehensive Preclinical Data Set On First Selective Drug For Patients With Systemic Mastocytosis At 2014 American Society of Hematology Annual Meeting 12/8/2014
Fate Therapeutics (FATE) Unveils Preclinical Findings Of Newly-Identified Small Molecule Modulator Combination For Ex Vivo Programming Of Mobilized Peripheral Blood 12/8/2014
Oncolytics Biotech Inc. (ONC.TO) Collaborators Present REOLYSIN And Checkpoint Inhibitor Combination Preclinical Data At American Association for Cancer Research Tumor Immunology And Immunotherapy Conference 12/5/2014
ZIOPHARM Oncology, Inc. (ZIOP.OB) And Intrexon Corporation Present Clinical And Preclinical Data From Immuno-Oncology Programs At Intrexon Corporation Tumor Immunology And Immunotherapy Meeting 12/4/2014
ARMGO Pharma Inc. And Servier Announce Advancement Of Rycal ARM210/S48168 Into Clinical Stage Program Targeting Duchenne Muscular Dystrophy 12/4/2014
Xenetic Biosciences Announces OncoHist™ Preclinical Data To Be Featured In A Poster Presentation At The American Society of Hematology Annual Meeting 12/4/2014
Aduro Biotech Announces Preclinical Data Presented At American Association for Cancer Research Tumor Immunology And Immunotherapy Conference 12/4/2014
Idera Pharmaceuticals, Inc. (IDRA) Announces Cancer Immunotherapy Regimen With Intratumoral IMO-2055 Demonstrated Potent And Systemic Anti-Tumor Activity In Preclinical Models 12/3/2014
Preclinical Data Published On AM-Pharma Holding BV’s recAP To Treat Ultra Rare Disease Hypophosphatasia 12/2/2014
AB Science (AB.PA) Advances Ultra-Selective SYK Kinase Inhibitor Into Full Preclinical Development 12/1/2014
Antibe Therapeutics Inc. Provides Update On Its Acute Pain Drug ATB-352 11/25/2014
Luoxis Announces Presentation Of Multiple Studies Validating Redoxsys As A Rapid And Non-Invasive Means Of Assessing Oxidative Stress 11/24/2014
Cardioxyl Pharmaceuticals HNO Prodrugs Show Effectiveness In Preclinical Models Following Oral Administration, Improve Hemodynamics In Chronic Diastolic Dysfunction 11/20/2014
Deciphera Pharmaceuticals Presents Data On Altiratinib (DCC-2701), An Advanced Multi-Targeted Kinase Inhibitor, At 26th EORTC-NCI-AACR Symposium On Molecular Targets And Cancer Therapeutics 11/20/2014
Kolltan Pharmaceuticals Inc. Presents KTN3379 Clinical And Preclinical Data At International Cancer Meeting 11/20/2014
Nektar Therapeutics (CA) (NKTR) Presents Preclinical Study Findings For Etirinotecan Pegol (NKTR-102) In Combination With A PARP Inhibitor In BRCA1-Deficient Cancer Model 11/20/2014
Inovio Pharmaceuticals (INO) Melanoma DNA Immunotherapy Inhibits Tumor Growth And Increases Survival In Preclinical Study 11/20/2014
Kadmon Corporation Presents Preclinical Data On Bi-Functional Anti-PD-L1/IL-15 Fusion Protein At EORTC-NCI-AACR Symposium 11/19/2014
Nuvilex (NVLX) Announces Preliminary Data From Preclinical Study of Effects of Its Pancreatic Cancer Treatment on Ascites Fluid Formation 11/19/2014
Alnylam Pharmaceuticals (ALNY) Presents New Pre-Clinical Data On RNAi Therapeutic Programs For Cardio-Metabolic Diseases At American Heart Association Scientific Sessions 2014 11/18/2014
Arch Therapeutics Reports Positive Preclinical Data From Study of AC5 Surgical Hemostatic Device™ In Animals Treated With Brilinta® (ticagrelor) 11/18/2014
Enzyme Bio-Systems Ltd. Announces An Independent Research Group Reported Breast Cancer Preventive Efficacy For A Novel Synthetic Triterpenoid 11/17/2014
Regulus Therapeutics, Inc. (RGLS) And Sanofi (SAN.PA) Present New Data Enhancing The Preclinical Profile Of RG-012, An Anti-Mir Targeting Microrna-21 For The Treatment Of Renal Dysfunction In Alport Syndrome Patients, At ASN's Kidney Week 2014 Meeting 11/17/2014
DelMar Pharmaceuticals Presents Preclinical Data Supporting VAL-083 As A Potential New Treatment In Glioblastoma At The Society Of Neuro-Oncology Annual Meeting 11/14/2014
AstraZeneca PLC (AZN) To Test Whether It Can Undo Effects Of Its Own Heart Drug Brilinta 11/13/2014
AM-Pharma Holding BV Presents Preclinical Data On Mode-Of-Action For recAP In Acute Kidney Injury At American Society of Nephrology Meeting 11/13/2014
AstraZeneca PLC (AZN) Announces Initiation of Development Program For BRILINTA (ticagrelor) Reversal Agent 11/13/2014
Cortice Biosciences Announces Results From Studies Evaluating Pipeline Candidates TPI 287 And CRT 001 In Preclinical Models Of Tauopathies And Alzheimer's Disease 11/12/2014
SanguiBioTech GmbH: Preclinical Trials Demonstrate: Sangui Hemoglobin Preparation Improves Oxygen Supply Of Vital Organs 11/11/2014
Preclinical Data For GenVec Inc. (GNVC)'s RSV Vaccine Candidate Presented At The 9th RSV Symposium 11/11/2014
TetraLogic Pharmaceuticals (TLOG) Announces Results Of Preclinical Studies In Hepatitis B 11/10/2014
Xencor Provides Data Updates On XmAb Bispecific Antibody Programs And Announces Presentations At Upcoming American Society of Hematology 2014 Annual Meeting 11/6/2014
Ablynx (ABLYF) To Present Pre-Clinical Proof-Of-Concept Results With Anti-Rsv Nanobody, Alx-0171, At 9th International Respiratory Syncytial Virus Symposium 11/6/2014
Innovimmune Biotherapeutics, Inc. To Present Superior Preclinical Therapeutic Efficacy Results In Rheumatoid Arthritis Of Its INV-17 ROR Gamma T Inhibitor Program At The 2014 American College of Rheumatology Annual Meeting 11/5/2014
Innate Pharma (IPH.PA ) : IPH4102 Preclinical Data Published In "Cancer Research" 11/3/2014
AB Science (AB.PA): Publication Of Preclinical Data On The Neuroprotective Effect Of Masitinib 10/31/2014
Loxo Oncology (LOXO) To Present Pre-Clinical Data On LOXO-101 At Upcoming European Organization for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research Symposium 10/30/2014
FDA Grants Kamada Ltd. (KMDA) Orphan Drug Designation For The Treatment Of Graft Versus Host Disease 10/29/2014
Celsion Corporation (CLSN) Presents Preclinical Data For Its TheraSilence™ Platform At The miRNA World Conference Workshop On miRNA Delivery 10/29/2014
CytRx Corporation (CYTR) Announces Publication Of Preclinical Glioblastoma Data In Neoplasia 10/29/2014
Ebola Clinical Trials: Big Name Players In The Ebola Race 10/28/2014
Celladon Corporation Announces Publication Of Data From Its Stem Cell Factor Gene Therapy Program In Circulation Heart Failure 10/27/2014
Profectus BioSciences, Inc. Receives $8.6 Million HHS Contract To Accelerate Ebola Vaccine Into Human Clinical Studies 10/22/2014
Profectus BioSciences, Inc. Receives Department Of The Army Funding For Studies Directed Toward The Development Of A VesiculoVax™ rVSV-Vectored Vaccine For Ebola And Marburg Viruses 10/22/2014
Omeros Corporation (OMER) Suspends Enrollment In Huntington's Disease Trial; Stock Down 11.36% At 8:40AM ET On Tuesday 10/21/2014
Immunovaccine Inc. Demonstrates Protection Against Lethal Anthrax Challenge With Rapid Acting, Single Dose Vaccine 10/21/2014
VG Life Sciences, Inc. (VGLS) Release: New Data Implicate Components Of Adaptive Immunity In Traumatic Brain Injury 10/20/2014
Epizyme (EPZM) Presents Pre-Clinical Data On EZH2 Inhibitor EPZ-6438 (E7438) In Models Of Synovial Sarcoma 10/17/2014
HHS Contracts With Profectus BioSciences, Inc. To Manufacture Ebola Vaccine For Animal Safety Studies 10/16/2014
Sihuan Pharmaceutical Sends Ebola Drug JK-05 To Africa, Eyes Clinical Trials 10/16/2014
BioSpecifics Technologies Corporation (BSTC) Announces Presentation Of Encouraging Preclinical Data For CCH From Collaborative Uterine Fibroid Study With Duke Medicine 10/16/2014
Cellular Biomedicine Group (CBMG) Launches Pre-Clinical Research Study For Chronic Obstructive Pulmonary Disease (COPD) 10/16/2014
Tekmira (TKMR) Presents Results Of Preclinical Studies With Hepatitis B Therapeutic 10/16/2014
Dicerna Pharmaceuticals (DRNA) Presents Preclinical Data For Investigational RNAi Therapeutic DCR-PH1 In Primary Hyperoxaluria Type 1 (PH1) At The 10th Annual Meeting Of The Oligonucleotide Therapeutics Society 10/15/2014
Compugen Ltd. (CGEN) Achieves Second Preclinical Milestone In Cancer Immunotherapy Collaboration With Bayer AG (BAYZF) 10/14/2014
Mologen AG (MOLGF.PK) Presents EnanDIM: A New Generation Of Immunomodulators 10/14/2014
Regulus Therapeutics, Inc. Presents New Preclinical Data On Multiple Programs And Provides Portfolio Overview At 10th Annual Oligonucleotide Therapeutics Society (OTS) Meeting 10/14/2014
Alnylam Pharmaceuticals (ALNY) Presents New Clinical And Pre-Clinical Data On RNAi Therapeutics At 10th Oligonucleotide Therapeutics Society (OTS) Meeting 10/14/2014
Tekmira (TKMR) To Present HBV Pre-Clinical Data At Meeting Of The Oligonucleotide Therapeutics Society 10/10/2014
Shionogi, Inc. Release: Novel Siderophore Cephalosporin S-649266 Pre-Clinical Results Suggest Potent Activity Against Multidrug-Resistant Gram-Negative Pathogens 10/9/2014
Protein Sciences Corporation Expects To Begin Testing Ebola Vaccine 10/7/2014
Kadimastem Received A Quick Response From The FDA: The Development Process For The Stem Cell-Based Drug For ALS Is Expected To Be Significantly Shortened 10/7/2014
Immunovaccine Inc. To Provide Update On Ongoing Ebola Virus And Cancer Vaccine Programs At 13th Annual Biotechnology Industry Organization (BIO) Investor Forum 10/6/2014
Kadimastem Approached The FDA Regarding Its ALS Treatment 10/6/2014
Regen BioPharma Completes Preclinical Experiments For dCellVax Breast Cancer Immune Therapy 10/2/2014
3-V Biosciences To Present Clinical And Preclinical Data For FASN Inhibitors At EORTC-NCI-AACR 2014 10/2/2014
OncoMed Pharmaceuticals, Inc. (OMED) Announces Selection Of First Small Molecule Product Candidate Targeting The Wnt Pathway Under Collaboration With Bayer Pharma AG 9/30/2014
REGENXBIO's NAV® Technology Demonstrates Correction Of Cardiovascular Symptoms Of MPS I In Animal Model 9/30/2014
Cell Reports Publication On The Mechanism Of Action Of NOXXON’s Anti-SDF-1 Spiegelmer® Olaptesed Pegol (NOX-A12) In Preclinical Multiple Myeloma Models 9/26/2014
OxThera, Inc. Release: Oxabact® Granted European Medicines Agency Orphan Drug Designation For Treatment Of SBS 9/23/2014
Novartis AG (NVS) Studies Muscle Atrophy By Sending Mice Into Space 9/23/2014
Sirona Biochem Launches Anti-aging Preclinical Studies 9/23/2014
Research Findings Demonstrate miRagen Therapeutics’ Drug Reverses Pulmonary Fibrosis 9/22/2014
Hemispherx Biopharma (HEB) Announces Primate Research Showing Alferon® LDO Protection From Pulmonary Damage Associated With Infection By Highly Pathogenic Influenza Virus 9/22/2014
Nektar Therapeutics (CA) (NKTR) Presents Positive Preclinical Data On Oral, Peripherally-Acting Kappa Agonist Molecules At 2014 American Academy Of Pain Management Meeting 9/19/2014
Cyclacel Pharmaceuticals, Inc. (CYCC)'s CYC065 CDK Inhibitor Demonstrates Therapeutic Potential In Acute Leukemias With Mixed Lineage Leukemia (MLL) Rearrangements 9/18/2014
BioLineRx Ltd. Presents Positive Preclinical Results In Treatment For AML Patients With FLT3 Mutations 9/17/2014
Alnylam Pharmaceuticals (ALNY) Presents New Pre-Clinical Data With ALN-CC5, A Subcutaneously Administered Rnai Therapeutic Targeting Complement Component C5 In Development For The Treatment Of Complement-Mediated Diseases 9/16/2014
Celator Pharmaceuticals, Inc. Announces Publication Of Preclinical Data For CPX-351 In Acute Lymphoblastic Leukemia Models 9/15/2014
Viamet Pharmaceuticals Receives Orphan Drug Designation For VT-1129 9/11/2014
GlaxoSmithKline (GSK)'s Experimental Ebola Vaccine Protects Monkeys For 10 Months 9/8/2014
Melinta Therapeutics (Formerly known as Rib-X Pharmaceuticals, Inc.) Demonstrates Potent In Vitro Activity Of New Antibiotic Class Against Gram Negative ESKAPE Pathogens 9/8/2014
Arch Therapeutics Announces Positive Preclinical Data From An Independent Study Of AC5 Surgical Hemostatic Device™ 9/8/2014
Novan Therapeutics’s Nitric Oxide Drug Candidate Inhibits Growth Of Papillomavirus In Translational Animal Model 9/8/2014
Shionogi & Co., Ltd. Presents Pre-Clinical And Phase I Results For S-649266, A Novel Siderophore Cephalosporine Antibiotic With Potential To Treat Multidrug-Resistant Gram-Negative Pathogens 9/8/2014
Blueprint Medicines Presents Positive Data On BLU-554 For Hepatocellular Carcinoma 9/8/2014
Melinta Therapeutics (Formerly known as Rib-X Pharmaceuticals, Inc.) And Hartford Hospital Demonstrate Delafloxacin's Potent In-Vitro Activity Against Complicated Urinary Tract Infection Pathogens 9/8/2014
Johnson & Johnson (JNJ) Jumps Into The Ebola Race With Collaboration Of Crucell (JNJ) And Bavarian Nordic (BAVA.CO); Human Trials To Start In Early 2015 9/4/2014
GamaMabs Pharma SA Announces Two Scientific Communications On Its AMHR2 Project 9/4/2014
Sirona Biochem Announces Positive Results In PK Study For Type 2 Diabetes 9/4/2014
Tricida Announces In-House Discovered Clinical Candidate In Cardiorenal Disease 9/4/2014
Aerpio Announces Publication Of Preclinical Data On AKB-9778 For Common Eye Diseases 9/3/2014
Chimerix, Inc. (CMRX)'s Brincidofovir Has In Vitro Activity Against Ebola 9/3/2014
Rhizen Pharmaceuticals S.A. To Present Preclinical Data Of Their First-In-Class Inflammation Assets, RP6503 And RP3128 For Treatment Of Various Respiratory Diseases 9/3/2014
SAGE Therapeutics Presents New Preclinical Data On SAGE-217 At Eilat Conference On New Anti-Epileptic Drugs 9/2/2014
Galleon Pharmaceuticals, Inc. Announces Publication Of Proof-Of-Concept Clinical Studies For GAL-021, Projected Use For The Emerging Perioperative Sleep Apnea Epidemic 9/2/2014
Biocryst Pharmaceuticals (BCRX) Expected To Jump Into Ebola Race In A Few Weeks 8/29/2014
IntelliPharmaCeutics Augments Its Rexista™ Oxycodone Development Program With Novel Overdose Deterrence Technology 8/29/2014
REGENX Biosciences, LLC: Attacking A Rare Disease At Its Source With Gene Therapy 8/27/2014
TetraLogic Pharmaceuticals (TLOG) To Present Data From Pre-Clinical Studies With Hepatitis B At The 2014 International Meeting On Molecular Biology Of Hepatitis B Viruses 8/27/2014
Cannabis Science Inc. Provides Updated Guidance On Its Current Pre-Clinical Drug Development Programs Beginning With The Scientific Cannabis Cultivation Programs In Europe And North America, Testing Multiple Cannabis Strains For Multiple Critical Ailments 8/27/2014
Ebola Vaccine Using Immunovaccine Inc.’s DepoVax Proves Highly Efficacious In Non-Human Primate Study 8/25/2014
INSYS Therapeutics Receives FDA Orphan Drug Designation For Its Pharmaceutical Cannabidiol As A Potential Treatment For Glioblastoma Multiforme 8/25/2014
Arch Therapeutics Announces Positive Preclinical Data From Its Study Of AC5 Surgical Hemostatic Device™ In Animals On Blood Thinner 8/25/2014
Ebola-Like Virus Beaten By Tekmira Pharmaceuticals Corporation (TKMR) Drug In Study 8/22/2014
Stemedica International Announces Pre-clinical Data Of Its Alzheimer’s Study 8/20/2014
Nuvilex (NVLX) Begins Preclinical Studies With Translational Drug Development To Determine If Nuvilex's Unique Cancer Treatment Can Slow Accumulation Of Malignant Ascites Fluid 8/20/2014
Novan Therapeutics To Present Antiviral Preclinical Results Of Nitric Oxide-Releasing Drug Candidates For The Treatment Of Papillomavirus 8/14/2014
CrystalGenomics Release: Polmacoxib Demonstrates Prevention And Treatment Effects In Colorectal Cancer 8/13/2014
Nuvilex (NVLX) Provides Update On Status Of Preclinical Studies At Translational Drug Development 8/13/2014
Scancell Release: Synergy Of SCIB1 With Checkpoint Inhibitors 8/12/2014
Cambridge's Sarepta Therapeutics (SRPT) Gets A Lift As Shelved Ebola Drug Offers Hope In Crisis 8/8/2014
PTC Therapeutics, Inc. (PTCT) Release: Orally Delivered Compounds, Which Selectively Modify RNA Splicing Prevent Deficits In Mouse Models Of Spinal Muscular Atrophy 8/7/2014
Idera Pharmaceuticals, Inc. (IDRA) And Collaborators Publish Promising Preclinical Data Targeting Microrna With Gene Silencing Oligonucleotide Technology 8/6/2014
MediciNova, Inc. Announces Positive Results Of MN-001 In Advanced NASH Mouse Model; Medicinova Requests A Meeting With FDA 8/5/2014
NanoViricides, Inc. (NNVC.PK) To Restart Its Anti-Ebola Virus Drug Development Program 8/4/2014
Cannabis Science Inc. Initiates Pre-Clinical Studies On Cannabinoid Formulations In Neurological Diseases Including Sleep Disorders With The Highly Reputable Institute For Health And Science On Ageing - INRCA - In Italy 8/4/2014
Syndax Pharmaceuticals Inc. Release: Entinostat Improves Treatment Outcomes When Combined With Immune Checkpoint Blockade In Preclinical Tumor Models 7/30/2014
Advanced Biologics Publishes Additional Osteoamp® Abstracts In The Bone And Joint Journal 7/24/2014
Sirona Biochem Announces Successful Completion of Two First Line Studies By Wanbang Biopharmaceuticals 7/23/2014
Glide Pharma Completes Successful Proof-Of-Concept Study With Novel Solid Dose Formulation Of Octreotide 7/22/2014
La Jolla Pharmaceutical Company (LJPC) Announces Positive Pre-Clinical Data For Oral Galectin-3 Inhibitor In Nonalcoholic Steatohepatitis (NASH) 7/15/2014
Anavex Life Sciences Corp. (AVXL.OB) 3-71 Highly Effective And Disease-Modifying Against All Major Alzheimer's Hallmarks In Preclinical Disease Model 7/14/2014
BrainStorm Cell Therapeutics Inc. Announces Publication Of Preclinical Multidose Study Of NurOwn 7/11/2014
Addex Therapeutics (ADXN.SW) ADX71441 Positive Results In Preclinical Model Of Nicotine Addiction 7/10/2014
Domainex Ltd Reports Success Of Its Lead Compound In Pre-Clinical Model Of COPD And Secures £1.4 Million Biomedical Catalyst Award 7/9/2014
Nuvilex (NVLX) Scheduled To Begin Preclinical Studies In Early August 7/9/2014
TRANSGENE (ENX:TNG) Announces Presentation Of Data On TG1050 Immunotherapy Against Chronic Hepatitis B And Provides Update On Its Joint Venture With Tasly Pharmaceutical In China 7/1/2014
Dicerna Pharmaceuticals (DRNA) Release: Researchers Demonstrate Promise Of Dicerna Investigational Therapy In Preclinical Model Of Primary Hyperoxaluria Type 1 (PH1) 6/30/2014
RedHill Biopharma Ltd. (RDHL) Announces Positive Preliminary Pre-Clinical Data With RHB-104 For The Treatment Of Type 1 Diabetes 6/26/2014
Flamel Technologies (FLML) Announces Positive Preclinical Results For Its Once-a-Week Formulation Of Exenatide 6/25/2014
Questcor Pharmaceuticals, Inc. (Headquarters) (QCOR) Closes Transaction To Acquire International Rights To Synacthen® And Synacthen® Depot 6/23/2014
Pieris Achieves Milestone Payment In Daiichi Sankyo, Inc. (4568.t) Collaboration To Develop Anticalin® Therapeutics 6/23/2014
Galectin Therapeutics Announces That Oral Treatment With Galectin-3 Inhibitor GR-MD-02 Is Efficacious In Preclinical Model Of Fatty Liver Disease With Fibrosis 6/23/2014
Success In Kadimastem’s First Pre-Clinical Trial For Treatment Of Amyotrophic Lateral Sclerosis (ALS) 6/19/2014
Arrowhead Research Corporation (ARWR) Announces New Clinical Candidate ARC-AAT For Treatment Of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease 6/19/2014
Apitope Progresses Graves' Disease Treatment 6/19/2014
Aeolus Pharmaceuticals Inc. (AOLS.OB) Announces Publication Of Data Demonstrating Efficacy Of AEOL 10150 In Animal CEES Model Of Mustard Gas Skin Exposure 6/18/2014
Lixte Biotechnology's Lead Compound Lb-100 Reported To Enhance Chemotherapy Effectiveness In Animal Models Of Liver Cancer 6/18/2014
Novogen Limited (NVGN) Touts Successful Proof-Of-Concept Studies For Trx-1 6/17/2014
Zealand Pharma  (ZEAL.CO) Presented New Data On Two Novel Peptide Therapeutics From Its Preclinical Diabetes Pipeline At The American Diabetes Association 74th Scientific Sessions 6/17/2014
Positive Preclinical Performance Of greenovation Biotech GmbH`s Lead Candidate moss-?Gal 6/12/2014
MediciNova, Inc. Announces Positive Results In Study Of MN-001 In Mouse Model Of Pulmonary Fibrosis 6/12/2014
D-Pharm Ltd.'s DP-b99 Prevents Abnormal Neuronal Plasticity And Pathological Brain Reorganization 6/12/2014
Five Scientific Communications At The European Academy Of Allergy And Clinical Immunology Congress Further Support DBV Technologies's EPIT™ Disease Modifying Effect 6/11/2014
BrainStorm Cell Therapeutics Inc. Expands Pipeline With Initiation Of Pre-Clinical Study In Autism 6/10/2014
Epizyme (EPZM) To Give Oral Presentation On Pre-Clinical Models And Early Clinical Observations Of EZH2 Inhibitor EPZ-6438 At American Society of Hematology Meeting On Lymphoma Biology August 10-13, 2014 6/10/2014
TetraLogic Pharmaceuticals (TLOG) Announces Preclinical Data Indicating Birinapant's Breadth Of Activity In Models Of Infectious Disease 6/9/2014
Alnylam Pharmaceuticals (ALNY) Presents New Pre-Clinical Data With Development Candidate For ALN-CC5, A Subcutaneously Administered RNAi Therapeutic Targeting Complement Component C5 In Development For The Treatment Of Complement-Mediated Diseases 6/9/2014
Cellectis And Accelera (Nerviano Medical Sciences (NervianoMS)) Sign An Agreement To Complete Preclinical Studies Of Cellectis’ Lead Product Candidate UCART19 6/5/2014
Galmed Pharmaceuticals Release: Recently Published Independent Research Supports The Importance Of Reverse Cholesterol Transport On NASH Pathogenesis 6/4/2014
Data Published By Researchers At The National Cancer Institute Further Identifies How Advaxis, Inc.'s Lm-LLO Immunotherapy Eradicates Tumors 6/4/2014
Implandata Successfully Launched Pre-Clinical Studies For New To The World Implantable 24h Extraocular Sensor For Intraocular Pressure Measurement At Glaucoma Patients 6/3/2014
Thrasos Therapeutics Presents Preclinical Data Demonstrating THR-184 Prevents Loss Of Kidney Function Following Acute Ischemic Injury 6/3/2014
Theralase Technologies Inc. (TLT.V) Discovers Anti-Cancer Memory Response 6/2/2014
Immunomedics, Inc. (IMMU) Reports Development Of Improved Cancer Immunotherapy At The 2014 Annual Meeting Of The American Society of Clinical Oncology 6/2/2014
Inotek Pharmaceuticals Corporation Announces Study Results Demonstrating Neuroprotective Properties Of Trabodenoson, Its Lead Drug Candidate For Glaucoma 5/30/2014
Sangamo BioSciences, Inc. (SGMO) Announces Publication Of Preclinical Data Demonstrating Gene Correction In SCID-X1 Human Hematopoietic Stem Cells 5/29/2014
Neogen Corporation (NEOG) Disinfectants Proven Effective Against Deadly Pig Virus 5/28/2014
Neurotrope Announces Publication Of Positive Human Cell Culture And Mouse Model Data Of Bryostatin 1 5/28/2014
Global Genomics Group Announces Completion Of Enrollment In GLOBAL Study With 7,500 Patients 5/27/2014
Bionure Inc.’s MS Drug Candidate Shows Positive Results For Myelin Repair In Cell Culture Assay 5/27/2014
Novogen Limited (NVGN) Identifies Highly Active Drug Candidates Against Prostate Cancer 5/27/2014
Alnylam Pharmaceuticals (ALNY) And Collaborators Publish Pre-Clinical Results With ALN-AS1, An RNAi Therapeutic Targeting Aminolevulinic Acid Synthase-1 (ALAS-1) For The Treatment Of Hepatic Porphyrias, In The Proceedings Of The National Academy Of Sciences 5/21/2014
Stemline Therapeutics, Inc. (STML) Announces Presentation Of SL-401 Preclinical Efficacy Data In Multiple Myeloma At The 2014 American Society of Clinical Oncology Annual Meeting 5/19/2014
Batu Biologics Authors Peer-Reviewed Publication On Intravenous Vitamin C As Adjuvant To Cancer Immunotherapy 5/16/2014
TRANSGENE (ENX:TNG) Reports Progress With Its Proprietary Oncolytic Immunotherapy To Treat Solid Tumors 5/15/2014
ChromaDex, Inc. Initiates Second Human Clinical Study For Its Caffeine Ingredient, PURENERGY® 5/14/2014
Cynapsus Therapeutics Announces No Buccal Mucosal Irritation In FDA Registration Study Of APL-130277 For Parkinson’s Disease 5/14/2014
RxGen, Inc. And ProLynx Present Data On Ocular Delivery Platform 5/13/2014
Da Volterra Presents New Data Supporting DAV132 As A Promising Candidate To Protect The Intestinal Flora And Prevent Severe Clostridium Difficile Infections 5/12/2014
Alnylam Pharmaceuticals (ALNY) Announces New RNAi Therapeutic Program For The Treatment Of Hepatitis B Virus (HBV) Infection And Reports An Up To 2.3 Log10 Reduction Of HBV Surface Antigen (HBsAg) In Chronically Infected Chimpanzees 5/12/2014
Aratana Therapeutics (PETX) Initiates Pivotal Study For AT-001 5/12/2014
Apitope Initiates Preclinical Development Of Peptide Therapy, ATX-F8-117, To Treat Factor VIII Intolerance 5/7/2014
Alnylam Pharmaceuticals (ALNY) Advances Development Candidate For ALN-AAT, A Subcutaneously Administered RNAi Therapeutic Targeting Alpha-1 Antitrypsin (AAT) In Development For The Treatment Of AAT Deficiency-Associated Liver Disease 5/6/2014
Cempra Pharmaceuticals, Inc. Presents Late-Breaker On Solithromycin's Anti NASH Effects In An Animal Model At DDW 2014 5/6/2014
MacroGenics, Inc. (MGNX) Presents Pre-Clinical Data On Inhibition Of Autoimmune Diseases With DART Candidate MGD010 At IMMUNOLOGY 2014 5/6/2014
Hemispherx Biopharma (HEB) Release: Alferon® N Effective Against MERS (Middle East Respiratory Syndrome) Virus In-Vitro 5/5/2014
RXi Pharmaceuticals (RXII) Announces Positive Results With RXI?109 In The Eyes Of Cynomolgus Monkeys As Part Of A Dose Range Finding Study 5/2/2014
Problem For Science? Lab Mice Get Stressed Out Around Men, But Not Women, McGill University Study 5/1/2014
Liquidia Technologies Inc. To Present New Data On Next-Generation Multivalent Pneumococcal Vaccine 5/1/2014
Complexa, Inc. Initiates First Clinical Trial Of CXA-10 for Acute Kidney Injury 5/1/2014
Catabasis Pharmaceuticals, Inc. Describes Modulation Of SREBP As Mechanism For CAT-2003 5/1/2014
Alnylam Pharmaceuticals (ALNY) Presents New Pre-Clinical Data On Rnai Therapeutics Targeting Transthyretin (TTR) For The Treatment Of TTR-Mediated Amyloidosis (ATTR) 4/29/2014
Anavex Life Sciences Corp. (AVXL.OB) Encouraged By Scientific Data Confirming Sigma-1 Receptor Agonist Is Potentially Disease-Modifying In Parkinson's Disease 4/29/2014